Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Attention Deficit Hyperactivity Disorder Market, by Drug Type
1.4.2 North America Attention Deficit Hyperactivity Disorder Market, by Demographics
1.4.3 North America Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
1.4.4 North America Attention Deficit Hyperactivity Disorder Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Attention Deficit Hyperactivity Disorder Market
Chapter 4. North America Attention Deficit Hyperactivity Disorder Market by Drug Type
4.1 North America Stimulants Market by Country
4.2 North America Attention Deficit Hyperactivity Disorder Market by Stimulants Type
4.2.1 North America Amphetamine Market by Country
4.2.2 North America Methylphenidate Market by Country
4.2.3 North America Lisdexamfetamine Market by Country
4.2.4 North America Dexmethylphenidate Market by Country
4.3 North America Non-stimulants Market by Country
4.4 North America Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type
4.4.1 North America Atomoxetine Market by Country
4.4.2 North America Guanfacine Market by Country
4.4.3 North America Clonidine Market by Country
4.4.4 North America Others Market by Country
Chapter 5. North America Attention Deficit Hyperactivity Disorder Market by Demographics
5.1 North America Adults Market by Country
5.2 North America Children Market by Country
Chapter 6. North America Attention Deficit Hyperactivity Disorder Market by Distribution Channel
6.1 North America Retail Pharmacy Market by Country
6.2 North America Hospital Pharmacy Market by Country
Chapter 7. North America Attention Deficit Hyperactivity Disorder Market by Country
7.1 US Attention Deficit Hyperactivity Disorder Market
7.1.1 US Attention Deficit Hyperactivity Disorder Market by Drug Type
7.1.1.1 US Attention Deficit Hyperactivity Disorder Market by Stimulants Type
7.1.1.2 US Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type
7.1.2 US Attention Deficit Hyperactivity Disorder Market by Demographics
7.1.3 US Attention Deficit Hyperactivity Disorder Market by Distribution Channel
7.2 Canada Attention Deficit Hyperactivity Disorder Market
7.2.1 Canada Attention Deficit Hyperactivity Disorder Market by Drug Type
7.2.1.1 Canada Attention Deficit Hyperactivity Disorder Market by Stimulants Type
7.2.1.2 Canada Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type
7.2.2 Canada Attention Deficit Hyperactivity Disorder Market by Demographics
7.2.3 Canada Attention Deficit Hyperactivity Disorder Market by Distribution Channel
7.3 Mexico Attention Deficit Hyperactivity Disorder Market
7.3.1 Mexico Attention Deficit Hyperactivity Disorder Market by Drug Type
7.3.1.1 Mexico Attention Deficit Hyperactivity Disorder Market by Stimulants Type
7.3.1.2 Mexico Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type
7.3.2 Mexico Attention Deficit Hyperactivity Disorder Market by Demographics
7.3.3 Mexico Attention Deficit Hyperactivity Disorder Market by Distribution Channel
7.4 Rest of North America Attention Deficit Hyperactivity Disorder Market
7.4.1 Rest of North America Attention Deficit Hyperactivity Disorder Market by Drug Type
7.4.1.1 Rest of North America Attention Deficit Hyperactivity Disorder Market by Stimulants Type
7.4.1.2 Rest of North America Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type
7.4.2 Rest of North America Attention Deficit Hyperactivity Disorder Market by Demographics
7.4.3 Rest of North America Attention Deficit Hyperactivity Disorder Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Eli Lilly And Company
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.2 Pfizer, Inc. (Global Blood Therapeutics, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.4 Lupin Limited
8.4.1 Company Overview
8.4.2 Financial Analysis
8.5 Novartis AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Approvals and Trials:
8.6 Takeda Pharmaceutical Company Limited
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.7 Mallinckrodt PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.8 Purdue Pharma L.P.
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Approvals and Trials:
8.9 Aytu BioPharma, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Product Launches and Product Expansions:
8.9.5.2 Approvals and Trials:
8.10. Supernus Pharmaceuticals, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Approvals and Trials:
Unique Offerings 
